| Literature DB >> 33497361 |
Jared S Rosenblum1, Herui Wang1, Pauline M Dmitriev1, Anthony J Cappadona1, Panagiotis Mastorakos2,3, Chen Xu1, Abhishek Jha4, Nancy Edwards2, Danielle R Donahue5, Jeeva Munasinghe5, Matthew A Nazari6, Russell H Knutsen7, Bruce R Rosenblum8, James G Smirniotopoulos9,10, Alberto Pappo11, Robert F Spetzler12, Alexander Vortmeyer13, Mark R Gilbert1, Dorian B McGavern3, Emily Chew14, Beth A Kozel7, John D Heiss2, Zhengping Zhuang1, Karel Pacak4.
Abstract
Mutations in EPAS1, encoding hypoxia-inducible factor-2α (HIF-2α), were previously identified in a syndrome of multiple paragangliomas, somatostatinoma, and polycythemia. HIF-2α, when dimerized with HIF-1β, acts as an angiogenic transcription factor. Patients referred to the NIH for new, recurrent, and/or metastatic paraganglioma or pheochromocytoma were confirmed for EPAS1 gain-of-function mutation; imaging was evaluated for vascular malformations. We evaluated the Epas1A529V transgenic syndrome mouse model, corresponding to the mutation initially detected in the patients (EPAS1A530V), for vascular malformations via intravital 2-photon microscopy of meningeal vessels, terminal vascular perfusion with Microfil silicate polymer and subsequent intact ex vivo 14T MRI and micro-CT, and histologic sectioning and staining of the brain and identified pathologies. Further, we evaluated retinas from corresponding developmental time points (P7, P14, and P21) and the adult dura via immunofluorescent labeling of vessels and confocal imaging. We identified a spectrum of vascular malformations in all 9 syndromic patients and in all our tested mutant mice. Patient vessels had higher variant allele frequency than adjacent normal tissue. Veins of the murine retina and intracranial dura failed to regress normally at the expected developmental time points. These findings add vascular malformation as a new clinical feature of EPAS1 gain-of-function syndrome.Entities:
Keywords: Angiogenesis; Development; Genetic diseases; Mouse models
Mesh:
Substances:
Year: 2021 PMID: 33497361 PMCID: PMC8021124 DOI: 10.1172/jci.insight.144368
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708
EPAS1 gain-of-function syndrome patient characteristics and malformations
Figure 1Intracranial malformations and rete mirabile in HIF-2α gain-of-function syndrome patients.
Representative images are shown. (A) Sagittal T1-weighted postcontrast MRI of the head of patient 1 shows a subarachnoid cavernous angioma (arrow). Prominent interstitial fluid or Virchow-Robins spaces are seen within the corpus callosum (double-lined arrows); these are seen throughout the parenchyma following veins (white circle). Prominent tentorial veins are also seen (arrowhead). (B) Axial T1-FLAIR (left) and T2-weighted (right) sequences of the same patient show the subarachnoid cavernous angioma (arrow) arising from veins. This corresponds to the blue line in A. (C) Reconstruction of TOF MR angiogram of patient 3 shows dysplastic segments of the internal carotid artery bilaterally (arrows). (D) Coronal CT of the neck with contrast of the same patient shows a plexiform jugular vein surrounding a dysplastic carotid, known as a rete mirabile, at the cranio-cervical junction on the right (arrow); volumetric reconstruction of the same CT of the neck demonstrating rete mirabile on the right and left (arrows). ICA, internal carotid artery; IJV, internal jugular vein.
Figure 2Extrinsic cervical spine venous malformations in HIF-2α gain-of-function syndrome patients.
Representative images are shown. (A) Axial CT of the neck with contrast of patient 1 shows cervical dysraphism at the level of C2 (left) due to a subfascial cavernous malformation of the upper neck (arrow). The malformation is continuous with the epidural veins (double-lined arrow) and large veins of the external spinal system (arrowhead). At the level of C3–4 (middle), the malformation (arrow) drains to a persistent segmental vein (arrowheads) of the spinal column bilaterally. These surround the vertebral artery (double-lined arrow). Large veins are seen throughout the soft tissues. Sagittal view of the left side of the same CT of the neck (right) showing the corresponding axial plane (green line). The posterior condylar emissary vein (arrow) is also seen draining to the malformation. (B) Posterior coronal view of the volumetric reconstruction of CT of the neck with contrast of patient 1 highlighting contrast and bone and excluding soft tissue demonstrates the veins (blue; arrowheads) entering and within the cavernous malformation (arrow) lined by persistent mesenchyme (red outline) extending from beneath the skull base down the length of the cervical spine. (C) Sagittal T1-weighted postcontrast MRI of the head demonstrates large sinusoidal veins (arrows) throughout the left lateral aspect of the neck of patient 2. (D) Coronal CT of the neck with contrast of patient 1 shows a venous malformation draining to the left jugular and subclavian veins (arrow).
Figure 3Meningeal and parenchymal venous malformations in HIF-2α gain-of-function syndrome patients.
(A) Midsagittal T1-weighted MRI of the cervical spine with contrast of patient 1 shows the cavernous malformation of the neck (arrow) and multiple contrast enhancing vessels behind the C4–7 vertebral bodies (arrowheads). Contrast enhancement in abnormal appearing regions of vertebral bodies is also seen (double-lined arrows). Adjacent slice of the same MRI shows contrast enhancement of the meninges connecting to the veins of the malformation (arrowheads) on the left. Abnormal enhancement of the bone and ligaments (double-lined arrows) is found to be continuous with contrast enhancement within the dura posterior to the vertebral bodies (dashed arrows). The neck malformation is again seen (arrow). (B) Posterior coronal view of volumetric reconstruction of the same 3D T1-weighted postcontrast sequence MRI excluding parenchyma and highlighting bone and contrast shows a venous malformation (asterisk) originating from the anterior spinal vein (ASV) corresponding to the intradural contrast enhancing vessels in A; the ASV is connected (arrowheads) to the tentorium (T). BA, basilar artery. (C) Axial T1-weighted postcontrast MRI of the same patient shows the veins in the dural nerve root sleeve (dashed arrow) draining the veins of the spinal cord (arrowheads) with a widened anterior median sulcus; the enlarged external spinal column veins are also seen (arrows). (D) Volumetric reconstruction of T1-weighted postcontrast MRI of the head of patient 2 shows a developmental configuration of the tentorial veins and sinuses on the left (arrow); the left transverse sinus (TS) is smaller than the right.
Figure 4Venous anomalies and malformations in HIF-2α gain-of-function syndrome mouse model.
Representative images are shown. (A) Axial view 3D volumetric reconstruction of micro-CT of the polymer-casted mouse model (MUT) shows a prominent confluence of sinuses (arrow) compared with control (CTRL) and a vascular malformation arising from the junction of the superior sagittal sinus and rostral rhinal sinus (double-lined arrow). Prominent occipital emissary veins (arrowheads) are seen in the mutant. (B) Sagittal ex vivo T1-weighted MRI (top) shows an enlarged vein of Galen (arrowhead) arising from a large superior sagittal sinus (arrow) in the mutant; the coronal slice (middle) corresponds to the green line in the sagittal view and shows prominent vessels throughout the parenchyma. Midsagittal section of another mutant (bottom) shows a lesion in the olfactory bulb (arrow) arising from large anomalous veins (arrowhead). The normal caliber of the vein of Galen (arrow) is shown in the control. (C) Midsagittal 3D volumetric reconstruction of micro-CT (left) of the mutant from B (bottom) shows the lesion in the olfactory bulb (arrow) and the draining vessel (arrowhead). Coronal histologic section (right) of the same sample at original magnification ×10 stained with H&E shows a subarachnoid cerebrospinal fluid (CSF) cavity (arrow) between the olfactory bulbs surrounding the anterior portion of the falx, which has large veins in it (arrowhead), most likely consistent with CSF-venous fistula, as supported by the retrograde perfusion of polymer into this space seen on micro-CT. (D) Gross photograph of a suspected cavernous malformation (arrow) arising from a branch of the inferior vena cava (arrowhead) in the mutant. The right auricle (not visualized) is ligated. H, heart; L, lung. H&E-stained histologic section of the specimen reveals blood-filled dilated vascular channels associated with organizing thrombotic material and reactive inflammation consistent with cavernous angioma. Scale bar: 60 μm.
Figure 5Failure of early vascular regression in EPAS1 gain-of-function mouse model leads to persistent venous anomalies and malformations.
(A) Representative images of intravital 2-photon microscopy of leptomeningeal and parenchymal vessels through a thinned skull window following retro-orbital i.v. injection for tomato lectin DyLight 488 and Evans blue demonstrated increased density and tortuosity of pial arterioles and venules and parenchymal capillaries in the mutant compared with the littermate control. Scale bar: 50 μm. Data represent the mean ± SEM. Quantification of n = 6 (3 mutant, 3 control) is shown; 2-tailed t test, P value equals 0.014. *P < 0.05. (B) H&E staining of the mouse model brain shows a developmentally large vein of Galen (arrow), large leptomeningeal and parenchymal veins (arrowheads), and cavernous angiomas arising directly from these veins (double-lined arrow); controls are shown. Large veins throughout enlarged Virchow-Robin spaces are also seen in the mutant. Scale bars: 200 μm (top left and top middle), 400 μm (top right); for the CTRL: 200 μm (bottom left and bottom middle), 400 μm (bottom right). (C) Representative images of isolectin B4 staining of the mouse model superficial plexus of the retina at postnatal time points 7, 14, and 21 days (P7–P21), during which the retinal vasculature of the mouse completes development, demonstrates that the plexiform network of veins fail to regress in the mutant compared with the control. This persists in the dura as evaluated at 5 months old.